+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Intravenous Immunoglobulin Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896241
  • Report
  • January 2020
  • Region: Global
  • 111 pages
  • Mordor Intelligence
UP TO OFF
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Biotest AG
  • CSL Behring
  • Grifols, S.A.
  • Kedrion S.p.A
  • Octapharma
  • MORE
Market Overview

Intravenous Immunoglobulin (IVIG) therapy is the use of a mixture of antibodies (immunoglobulins) to treat health conditions including primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain-Barré syndrome, and in certain other infections. Depending on the formulation it can be injected into a muscle, a vein, or under the skin.

Increase in geriatric population, the prevalence of immunodeficiency disorders and bleeding disorders have led to an increase in deamnd for novel intravenous immunoglobulin therapies. This has led to increase in the adoption rate of these therapies. Hence these factors have helped the market growth. However, stringent regulatory approval processes and regulations, and the high cost of therapy have been restraining the growth of the market.

Scope of the Report

Intravenous Immunoglobulin (IVIG) therapy is the use of a mixture of antibodies (immunoglobulins) to treat health conditions including primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain-Barré syndrome, and in certain other infections. Depending on the formulation it can be injected into the muscle, a vein, or under the skin.

In the report, a detailed analysis of the intravenous immunoglobulin market is provided. The market is evaluated by collating revenues generated across segments, categorized by Product, Application, and Geography.

Key Market Trends

Primary Immunodeficiency Diseases Treatment is Expected to Register a High CAGR

As per a report by Christine McCusker et al., published in Allergy, Asthma & Clinical Immunology Journal, 2018, Primary immunodeficiency diseases are more frequent than previously believed, with an estimated prevalence of 1 in 1200 live births. IgA deficiency is the most common PID, occurring in approximately 1 in 300 to 1 in 500 persons.

Intravenous immunoglobulin (IVIG) therapy has been used in primary immunodeficiency diseases (PI), other immune deficiency disorders. There are several specific medical therapies available for people with PI with antibody deficiency that account for more than half of the primary immunodeficiencies. These illnesses, such as Common Variable Immune Deficiency (CVID), X-Linked Agammaglobulinemia (XLA) and other disorders, are characterized by a lack of and/or impaired antibody function.

Hence, with the availability of IVIG therapies for treating the high prevalent primary immunodeficiency diseases, the market is expected to grow in the future.

North America is Expected to Dominate the Intravenous Immunoglobulin Market

The North American countries like the United States (US) and Canada have a developed and well-structured health care system. These systems also encourage research and development. These policies encourage global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players.

Furthermore, these countries have a large portion of the population that is insured. This enables this population to get medicines and therapies at subsidized rates. Hence, as increasing demand is met by the presence of global players in the region, the market is further expected to increase.

Competitive Landscape

The majority of the intravenous immunoglobulin therapies are being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the market grow.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biotest AG
  • CSL Behring
  • Grifols, S.A.
  • Kedrion S.p.A
  • Octapharma
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Geriatric Population
4.2.2 Increase in Adoption of Immunoglobulin Treatment
4.2.3 Growth in Prevalence of Immunodeficiency Diseases and Bleeding Disorders
4.3 Market Restraints
4.3.1 Stringent Government Regulations
4.3.2 High Cost of Therapy
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Type
5.1.1 IGG
5.1.2 IGA
5.1.3 IGM
5.1.4 IGE
5.1.5 IGD
5.2 By Application
5.2.1 Hypogammaglobulinemia
5.2.2 Chronic Inflammatory Demyelinating polyneuropathy (CIDP)
5.2.3 Primary Immunodeficiency Diseases
5.2.4 Myasthenia Gravis
5.2.5 Multifocal Motor Neuropathy
5.2.6 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bio Products Laboratory Ltd.
6.1.2 Biotest AG
6.1.3 China Biologic Products Holdings, Inc.
6.1.4 CSL Behring
6.1.5 Grifols, S.A.
6.1.6 Kedrion S.p.A
6.1.7 LFB SA and Shanghai RAAS Blood Products Co., Ltd.
6.1.8 Octapharma
6.1.9 Takeda Pharmaceutical Company Limited

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bio Products Laboratory Ltd.
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Behring
  • Grifols, S.A.
  • Kedrion S.p.A
  • LFB SA and Shanghai RAAS Blood Products Co., Ltd.
  • Octapharma
  • Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown
Adroll
adroll